Renal Cell Carcinoma

RCC Treatment During the COVID-19 Pandemic: A Patient Perspective

The COVID-19 pandemic has impacted treatment decisions for providers. However, it is the responsibility of the patient to make final treatment decisions. A study...

Racial Disparities in RCC Overall Survival

Despite presenting at a younger age and with lower-stage disease, Black  patients with renal cell carcinoma (RCC) have poorer overall survival (OS) than White...

Analysis of Everolimus Plus Bevacizumab as First-Line Advanced Papillary Variant RCC Treatment

Previously published outcomes of a phase II trial found that everolimus plus bevacizumab was an effective treatment for patients with papillary renal cell carcinoma...

RCC Survivors Commonly Experience Fear of Recurrence

Distress and fear of recurrence often plague patients with cancer. A study assessed how emotional well-being is connected to clinical characteristics of localized renal...
ESMO Introduces Scale That Optimizes Treatment Selection for Cancer

TMSB10 a Biomarker of Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is a common urological malignancy. Key to the management of patients with ccRCC is identification of novel biomarkers...
Systemic Therapy after IO-VEGF

Systemic Therapy after IO-VEGF

Several therapeutic combinations of immune-oncology (IO) plus vascular endothelial growth factor (VEGF) regimens have demonstrated positive results in phase 3 trials.
Immune Checkpoint Therapy plus Cytoreductive Surgery

Immune Checkpoint Therapy plus Cytoreductive Surgery

Patients with metastatic renal cell carcinoma (mRCC) gain clinical benefit from cytoreductive surgery, including cytoreductive nephrectomy and metastasectomy.

Journal Reading List

Advertisement
Advertisement
click me